Gain Therapeutics (GANX) FCF Margin (2020 - 2023)

Gain Therapeutics has reported FCF Margin for 4 years, with the latest figure at 7663.03% in Q1 2023.

• On a quarterly basis, FCF Margin fell 220772.0% year-over-year to 7663.03% in Q1 2023; TTM through Dec 2023 was 34217.53%, a 2364633.0% decrease from a year earlier, with the FY2023 full-year figure at 34217.53%, down 2364633.0% from the prior year.
• FCF Margin was 7663.03% for Q1 2023 at Gain Therapeutics, down from 5358.05% in the prior quarter.
• The five-year high for FCF Margin was 3632.9% in Q2 2021, with the low at 53869.71% in Q1 2021.
• Average FCF Margin over 4 years is 12588.35%, with a median of 8958.1% recorded in 2021.
• The sharpest annual moves came in 2021 and 2022: FCF Margin sank 4251480 bps in 2021, then surged 4841440 bps in 2022.
• Over 4 years, FCF Margin stood at 14641.7% in 2020, then soared by 39 bps to 8958.1% in 2021, then soared by 40 bps to 5358.05% in 2022, then tumbled by 43 bps to 7663.03% in 2023.
• The last three FCF Margin figures came in at 7663.03% (Q1 2023), 5358.05% (Q2 2022), and 5455.31% (Q1 2022), per Business Quant data.